Intellia Reports Positive Phase 3 HAELO Trial Results for Lonvo-z
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Clinical Trial Success: The Phase 3 HAELO trial demonstrated an 87% reduction (p<0.0001) in mean monthly attacks for the lonvo-z group, indicating significant efficacy in hereditary angioedema (HAE) patients and suggesting a potential market breakthrough.
- Increased Attack-Free Rate: 62% of patients in the lonvo-z group were entirely attack-free and therapy-free during the six-month efficacy evaluation period, compared to only 11% in the placebo group (p<0.0001), highlighting lonvo-z's substantial advantage in improving patient quality of life.
- Good Safety Profile: The treatment-emergent adverse events (TEAEs) in the lonvo-z group were all mild or moderate, with no serious adverse events observed, demonstrating the drug's good tolerability and laying a solid foundation for future market promotion.
- Regulatory Progress: Intellia initiated the biologics license application (BLA) for lonvo-z in April, with expectations for FDA approval and U.S. launch in the first half of 2027, marking a strategic advancement in gene editing therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTLA
Wall Street analysts forecast NTLA stock price to rise
22 Analyst Rating
9 Buy
12 Hold
1 Sell
Moderate Buy
Current: 12.350
Low
4.00
Averages
16.50
High
54.00
Current: 12.350
Low
4.00
Averages
16.50
High
54.00
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intellia Reports Positive Phase 3 HAELO Trial Results for Lonvo-z
- Clinical Trial Success: The Phase 3 HAELO trial demonstrated an 87% reduction (p<0.0001) in mean monthly attacks for the lonvo-z group, indicating significant efficacy in hereditary angioedema (HAE) patients and suggesting a potential market breakthrough.
- Increased Attack-Free Rate: 62% of patients in the lonvo-z group were entirely attack-free and therapy-free during the six-month efficacy evaluation period, compared to only 11% in the placebo group (p<0.0001), highlighting lonvo-z's substantial advantage in improving patient quality of life.
- Good Safety Profile: The treatment-emergent adverse events (TEAEs) in the lonvo-z group were all mild or moderate, with no serious adverse events observed, demonstrating the drug's good tolerability and laying a solid foundation for future market promotion.
- Regulatory Progress: Intellia initiated the biologics license application (BLA) for lonvo-z in April, with expectations for FDA approval and U.S. launch in the first half of 2027, marking a strategic advancement in gene editing therapies.
See More
Buffett's Investment Strategy and Healthcare Opportunities
- Investment Legacy: Warren Buffett has led Berkshire Hathaway to market-beating returns over 60 years by focusing on industries and companies with competitive advantages, and new CEO Greg Abel has pledged to continue this investment philosophy.
- Healthcare Sector Absence: Despite a diverse portfolio, Berkshire Hathaway is almost entirely absent from the healthcare sector, holding only kidney care giant DaVita, which Buffett added in 2011, while Abel closed the position in UnitedHealth Group in Q1 this year.
- Healthcare Investment Opportunities: The healthcare industry offers a wide range of investment options, with aggressive investors potentially targeting high-growth pharmaceutical companies like Eli Lilly, while conservative investors may prefer dividend-paying companies like Johnson & Johnson and Abbott Laboratories for steady earnings growth.
- Independent Investment Decisions: While it is valuable to follow the investment decisions of Buffett and Abel, investors should also consider the high-potential healthcare sector and make independent investment choices to capitalize on growth opportunities in this field.
See More
Buffett and Abel's Investment Strategies
- Investment Legacy: Warren Buffett has led Berkshire Hathaway to market-beating returns over the past sixty years, and new CEO Greg Abel promises to continue this successful path, demonstrating stability and continuity in the company's leadership.
- Portfolio Analysis: Berkshire Hathaway's largest holding is Apple, and although Buffett typically avoids tech stocks, he opened a position in Alphabet last year, with Abel increasing it in Q1 this year, indicating a cautious interest in the tech sector.
- Healthcare Sector Absence: Despite a diverse portfolio, the healthcare sector is almost entirely absent, with only DaVita added in 2011, and Abel closing the position in UnitedHealth Group in Q1, reflecting a potential missed growth opportunity in this vital industry.
- Independent Investor Thinking: While Buffett and Abel's investment strategies are worth following, investors should make independent decisions based on their own needs and resources, as the healthcare sector offers diverse investment opportunities, particularly in biotech and pharmaceuticals, which could yield significant returns.
See More
FDA Issues Draft Guidance to Accelerate Gene Therapy Development
- Draft Guidance Release: The FDA has issued a draft guidance aimed at accelerating the R&D process for gene and cell therapies by leveraging existing scientific and regulatory knowledge, which is expected to significantly enhance the approval efficiency of therapeutic products.
- Streamlined Regulatory Submissions: The guidance will clarify how sponsors can utilize publicly available information and established platform knowledge, including chemistry, manufacturing, and controls (CMC) data, to simplify regulatory submissions for human gene therapy products, thereby reducing compliance costs for companies.
- Early Engagement Recommendations: The FDA encourages companies to engage with it before submitting an IND application, including participating in Initial Targeted Engagement for Regulatory Advice on CBER/CDER Products (INTERACT) and pre-IND meetings, to ensure their development plans align with regulatory expectations, thus increasing their chances of success.
- Significant Industry Impact: The release of this draft guidance is likely to have a positive impact on leading gene and cell therapy biopharma companies, such as CRISPR Therapeutics and Intellia Therapeutics, potentially accelerating their product launch timelines and fostering overall industry growth.
See More
Intellia Announces HAELO Clinical Trial Data Presentation
- Clinical Trial Data Presentation: Intellia Therapeutics will present data from the HAELO clinical trial at the 2026 EAACI Annual Congress, indicating the potential of its CRISPR gene editing therapy, lonvo-z, to revolutionize treatment standards for hereditary angioedema (HAE).
- Key Presentation Schedule: The company is set to deliver an oral presentation on June 13, showcasing results from a global randomized double-blind trial, which is expected to garner significant attention and enhance Intellia's market position.
- Poster Presentation Focus: Additionally, Intellia will present a poster detailing the treatment barriers faced by HAE patients in Europe, aiming to raise awareness of the condition and promote better treatment options, potentially fostering future collaborations and research.
- Regulatory Recognition: Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT designations from the FDA, highlighting its innovative potential in HAE treatment and likely providing significant market opportunities and investor confidence for the company.
See More
Intellia Reports Positive Phase 3 Data for Lonvo-z, Plans U.S. Launch in 2027
- Clinical Trial Success: Intellia's Phase 3 HAELO trial demonstrated that a single infusion of lonvo-z reduced HAE attacks by 87%, highlighting its potential as an innovative treatment that could significantly enhance patient quality of life.
- Regulatory Application Progress: The company has initiated a rolling Biologics License Application (BLA) for lonvo-z, with plans to complete the submission in the second half of 2026, which, if approved, will provide a unique treatment option for HAE patients and further solidify Intellia's leadership in gene editing.
- Strong Financial Position: As of March 31, 2026, Intellia reported $517.2 million in cash and cash equivalents, and with the $207 million raised from the public offering in April, the company expects to fund operations through at least 2028, ensuring the market launch of lonvo-z.
- Clinical Trials Resumed: Intellia has resumed patient screening for the MAGNITUDE and MAGNITUDE-2 trials of nex-z, with plans to complete patient enrollment in the second half of 2026, further advancing the treatment landscape for ATTR amyloidosis.
See More
Intellia Reports Positive Phase 3 HAELO Trial Results for Lonvo-z
- Clinical Trial Success: The Phase 3 HAELO trial demonstrated an 87% reduction (p<0.0001) in mean monthly attacks for the lonvo-z group, indicating significant efficacy in hereditary angioedema (HAE) patients and suggesting a potential market breakthrough.
- Increased Attack-Free Rate: 62% of patients in the lonvo-z group were entirely attack-free and therapy-free during the six-month efficacy evaluation period, compared to only 11% in the placebo group (p<0.0001), highlighting lonvo-z's substantial advantage in improving patient quality of life.
- Good Safety Profile: The treatment-emergent adverse events (TEAEs) in the lonvo-z group were all mild or moderate, with no serious adverse events observed, demonstrating the drug's good tolerability and laying a solid foundation for future market promotion.
- Regulatory Progress: Intellia initiated the biologics license application (BLA) for lonvo-z in April, with expectations for FDA approval and U.S. launch in the first half of 2027, marking a strategic advancement in gene editing therapies.
See More
Buffett's Investment Strategy and Healthcare Opportunities
- Investment Legacy: Warren Buffett has led Berkshire Hathaway to market-beating returns over 60 years by focusing on industries and companies with competitive advantages, and new CEO Greg Abel has pledged to continue this investment philosophy.
- Healthcare Sector Absence: Despite a diverse portfolio, Berkshire Hathaway is almost entirely absent from the healthcare sector, holding only kidney care giant DaVita, which Buffett added in 2011, while Abel closed the position in UnitedHealth Group in Q1 this year.
- Healthcare Investment Opportunities: The healthcare industry offers a wide range of investment options, with aggressive investors potentially targeting high-growth pharmaceutical companies like Eli Lilly, while conservative investors may prefer dividend-paying companies like Johnson & Johnson and Abbott Laboratories for steady earnings growth.
- Independent Investment Decisions: While it is valuable to follow the investment decisions of Buffett and Abel, investors should also consider the high-potential healthcare sector and make independent investment choices to capitalize on growth opportunities in this field.
See More
Buffett and Abel's Investment Strategies
- Investment Legacy: Warren Buffett has led Berkshire Hathaway to market-beating returns over the past sixty years, and new CEO Greg Abel promises to continue this successful path, demonstrating stability and continuity in the company's leadership.
- Portfolio Analysis: Berkshire Hathaway's largest holding is Apple, and although Buffett typically avoids tech stocks, he opened a position in Alphabet last year, with Abel increasing it in Q1 this year, indicating a cautious interest in the tech sector.
- Healthcare Sector Absence: Despite a diverse portfolio, the healthcare sector is almost entirely absent, with only DaVita added in 2011, and Abel closing the position in UnitedHealth Group in Q1, reflecting a potential missed growth opportunity in this vital industry.
- Independent Investor Thinking: While Buffett and Abel's investment strategies are worth following, investors should make independent decisions based on their own needs and resources, as the healthcare sector offers diverse investment opportunities, particularly in biotech and pharmaceuticals, which could yield significant returns.
See More
FDA Issues Draft Guidance to Accelerate Gene Therapy Development
- Draft Guidance Release: The FDA has issued a draft guidance aimed at accelerating the R&D process for gene and cell therapies by leveraging existing scientific and regulatory knowledge, which is expected to significantly enhance the approval efficiency of therapeutic products.
- Streamlined Regulatory Submissions: The guidance will clarify how sponsors can utilize publicly available information and established platform knowledge, including chemistry, manufacturing, and controls (CMC) data, to simplify regulatory submissions for human gene therapy products, thereby reducing compliance costs for companies.
- Early Engagement Recommendations: The FDA encourages companies to engage with it before submitting an IND application, including participating in Initial Targeted Engagement for Regulatory Advice on CBER/CDER Products (INTERACT) and pre-IND meetings, to ensure their development plans align with regulatory expectations, thus increasing their chances of success.
- Significant Industry Impact: The release of this draft guidance is likely to have a positive impact on leading gene and cell therapy biopharma companies, such as CRISPR Therapeutics and Intellia Therapeutics, potentially accelerating their product launch timelines and fostering overall industry growth.
See More
Intellia Announces HAELO Clinical Trial Data Presentation
- Clinical Trial Data Presentation: Intellia Therapeutics will present data from the HAELO clinical trial at the 2026 EAACI Annual Congress, indicating the potential of its CRISPR gene editing therapy, lonvo-z, to revolutionize treatment standards for hereditary angioedema (HAE).
- Key Presentation Schedule: The company is set to deliver an oral presentation on June 13, showcasing results from a global randomized double-blind trial, which is expected to garner significant attention and enhance Intellia's market position.
- Poster Presentation Focus: Additionally, Intellia will present a poster detailing the treatment barriers faced by HAE patients in Europe, aiming to raise awareness of the condition and promote better treatment options, potentially fostering future collaborations and research.
- Regulatory Recognition: Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT designations from the FDA, highlighting its innovative potential in HAE treatment and likely providing significant market opportunities and investor confidence for the company.
See More
Intellia Reports Positive Phase 3 Data for Lonvo-z, Plans U.S. Launch in 2027
- Clinical Trial Success: Intellia's Phase 3 HAELO trial demonstrated that a single infusion of lonvo-z reduced HAE attacks by 87%, highlighting its potential as an innovative treatment that could significantly enhance patient quality of life.
- Regulatory Application Progress: The company has initiated a rolling Biologics License Application (BLA) for lonvo-z, with plans to complete the submission in the second half of 2026, which, if approved, will provide a unique treatment option for HAE patients and further solidify Intellia's leadership in gene editing.
- Strong Financial Position: As of March 31, 2026, Intellia reported $517.2 million in cash and cash equivalents, and with the $207 million raised from the public offering in April, the company expects to fund operations through at least 2028, ensuring the market launch of lonvo-z.
- Clinical Trials Resumed: Intellia has resumed patient screening for the MAGNITUDE and MAGNITUDE-2 trials of nex-z, with plans to complete patient enrollment in the second half of 2026, further advancing the treatment landscape for ATTR amyloidosis.
See More
